Friday, 22 April 2016

FDA - Data Integrity and Compliance With CGMP


The U.S. Food and Drug Administration (FDA) has released an important draft guidance for industry. the title is: "Data Integrity and Compliance With CGMP Guidance for Industry."

Data integrity refers to maintaining and assuring the accuracy and consistency of data over its entire life-cycle, and is a critical aspect to the design, implementation and usage of any system which stores, processes, or retrieves information. Data integrity is fundamental in a pharmaceutical quality system which ensures that medicines are of the required quality.

The introduction to the FDA guidance reads:

"The purpose of this guidance is to clarify the role of data integrity in current good manufacturing practice (CGMP) for drugs, as required in 21 CFR parts 210, 211, and 212. Part 210 covers Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs; General; part 211 covers Current Good Manufacturing Practice for Finished Pharmaceuticals; and part 212 covers Current Good Manufacturing Practice for Positron Emission Tomography Drugs. This guidance provides the Agency’s current thinking on the creation and handling of data in accordance with CGMP requirements.

FDA expects that data be reliable and accurate (see the “Background” section). CGMP regulations and guidance allow for flexible and risk-based strategies to prevent and detect data integrity issues. Firms should implement meaningful and effective strategies to manage their data integrity risks based upon their process understanding and knowledge management of technologies and business models."

The draft guidance can be accessed here.




Posted by Dr. Tim Sandle

Special offers